CRNX Crinetics Pharmaceuticals, ...


$ 43.33 $ 1.78 (4.28 %)    

Friday, 21-Nov-2025 14:09:51 EST
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
$ 41.92
$ 43.25 x 63
$ 43.39 x 11
$ 41.92 - $ 43.72
$ 24.10 - $ 60.34
972,534
na
2.26B
$ 0.95
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 crinetics-randomizes-first-patient-in-phase-3-carefndr-trial-of-oral-paltusotine-for-carcinoid-syndrome

CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics'...

 citizens-maintains-market-outperform-on-crinetics-pharmaceuticals-lowers-price-target-to-108

Citizens analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and lowers the...

 oppenheimer-maintains-outperform-on-crinetics-pharmaceuticals-raises-price-target-to-87

Oppenheimer analyst Leland Gershell maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and raises the price...

 morgan-stanley-maintains-overweight-on-crinetics-pharmaceuticals-raises-price-target-to-77

Morgan Stanley analyst Jeffrey Hung maintains Crinetics Pharmaceuticals (NASDAQ: CRNX) with a Overweight and raises the pric...

 goldman-sachs-maintains-neutral-on-crinetics-pharmaceuticals-raises-price-target-to-40

Goldman Sachs analyst Richard Law maintains Crinetics Pharmaceuticals (NASDAQ: CRNX) with a Neutral and raises the price ta...

 fda-approves-crinetics-pharmas-first-daily-pill-for-rare-growth-disorder

On Thursday, the U.S.

Core News & Articles

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The m...

 crinetics-pharmaceuticals-blackberry-perpetua-resources-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceutical...

 assessing-crinetics-pharmaceuticals-insights-from-4-financial-analysts

Throughout the last three months, 4 analysts have evaluated Crinetics Pharmaceuticals (NASDAQ: CRNX), offering a diverse set of...

 jmp-securities-maintains-market-outperform-on-crinetics-pharmaceuticals-raises-price-target-to-143

JMP Securities analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ: CRNX) with a Market Outperform and rai...

Core News & Articles

Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The ...

 baird-maintains-outperform-on-crinetics-pharmaceuticals-raises-price-target-to-62

Baird analyst Brian Skorney maintains Crinetics Pharmaceuticals (NASDAQ: CRNX) with a Outperform and raises the price target...

 crinetics-pharmaceuticals-receives-fda-approval-for-palsonify-palsonify-is-expected-to-be-available-in-the-us-in-early-october

SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) today announced that the U.S.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION